News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


EDG Capital, Inc Announces Filing of Investigational New Drug Application With FDA (Business Wire)EDG Capital, Inc., a developer of nuclear pharmaceuticals for therapeutic use in the treatment of cancer, announced today that, on June 4, 2001, its wholly owned subsidiary Isotope Solutions, Inc. filed an Investigational New Drug application with the Food and Drug Administration.- Jun 05 1:50 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010605/2917.html

Posted on: 06/05/2001

"Yahoo - EDG Capital, Inc Announces Filing of Investigational New Drug Application With FDA"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
EDGN.OB
2.62
+0.00
delayed 20 mins - disclaimer

Tuesday June 5, 1:50 pm Eastern Time

Press Release

EDG Capital, Inc Announces Filing of Investigational New Drug Application With FDA

GARDEN CITY, N.Y.--(BUSINESS WIRE)--June 5, 2001--EDG Capital, Inc. (OTCBB: EDGN - news), a developer of nuclear pharmaceuticals for therapeutic use in the treatment of cancer, announced today that, on June 4, 2001, its wholly owned subsidiary Isotope Solutions, Inc. (ISI) filed an Investigational New Drug (IND) application with the Food and Drug Administration.

The application requests permission to begin testing ISI's Radioactive Cisplatin technology in patients with liver cancer. Medical research groups managed by ISI will be conducting the testing.

"This is a major milestone in the development of this exciting new technology," said Jack Schwartzberg, Chief Executive Officer, President and Chairman of EDG Capital. "We are ready to begin testing this technology in liver cancer patients as soon as we get clearance from the FDA," he added.

The radioactive cisplatin used in ISI's Radioactive Cisplatin technology, 195mPt-Cisplatin, is chemically identical to standard cisplatin except that the platinum it contains has been made radioactive. Standard cisplatin is an effective and widely used chemotherapeutic agent for the treatment of various types of cancers. Cisplatin contains the element platinum and works by binding with tumor cell DNA, thereby disrupting its reproduction. Radioactive Cisplatin is designed to deliver high doses of radioactivity directly into the tumor cells.

It is well established that directed radiation can kill tumor cells effectively. In fact, many types of cancers are treated by external beam radiation and interstitial seed brachytherapy implants. Unfortunately, these radiation techniques are often unable to deliver therapeutic doses to the tumor without damaging surrounding normal tissues. Radioactive Cisplatin will take advantage of cisplatin's ability to bind directly to tumor cell DNA and deliver intense, localized radiation within solid tumors. This in turn should minimize injury to surrounding tissues and organs.

"Radioactive Cisplatin represents the next step forward in the platinum-based treatment of cancers," continued Mr. Schwartzberg. "Our Radioactive Cisplatin may find future application in the treatment many types of cancers, including liver, bladder, lung, brain, gastric, head and neck, pancreatic, esophageal, gynecological, breast, colon and prostate. By enhancing cisplatin's already well-recognized effectiveness with targeted tumor-destroying radiation, we hope to improve substantially the current treatment of many cancers."

About EDG Capital, Inc. Through its wholly-owned subsidiary, Isotope Solutions, Inc., EDG Capital is engaged in the research, development and testing of nuclear pharmaceuticals for therapeutic use in the treatment of the most lethal forms of cancer. Internationally renowned clinicians, who are under management contracts with Isotope Solutions Inc., conduct research for the company.

Legal Disclaimers: This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results of operations may differ materially from those projected or suggested in the forward-looking statements. The forward-looking statements contained herein represent EDG Capital, Inc.'s judgment as of the date of this release, and EDG Capital, Inc. cautions investors not to place undue reliance on such statements.


Contact:
     EDG Capital, Inc., New York
     Shragie David Aranoff
     Vice President
     516/222-5154
     shragie@isotopesolutions.com
          or
     Rubenstein Associates, Inc., New York
     Patricia Amerman
     Vice President
     212/843-8049
     pamerm@rubenstein.com

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:EDG Capital Inc (OTC BB:EDGN.OB - news)
Related News Categories: biotech, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740